OUR GOAL
To lead the way in precision gene therapies for neurological disorders
To lead the way in precision gene therapies for neurological disorders
Avrion Therapeutics was founded in 2020 based on 10+ years of research from the Brain Mind Institute and Bertarelli Foundation Gene Therapy Platform at EPFL - the Swiss Federal Institute of Technology Lausanne led by the groups of Dr. Bernard Schneider and Prof. Brian McCabe.
Our immediate mission is to develop proof of clinical efficacy for novel treatments for amyotrophic lateral sclerosis (ALS) also known as motor neuron disease (MND). Our first product candidate AVR-001 is designed to treat ALS associated with aberrations of SOD1. Our second product candidate AVR-002 is designed to treat all ALS patients.
Our immediate mission is to develop proof of clinical efficacy for novel treatments for amyotrophic lateral sclerosis (ALS) also known as motor neuron disease (MND). Our first product candidate AVR-001 is designed to treat ALS associated with aberrations of SOD1. Our second product candidate AVR-002 is designed to treat all ALS patients.
